Merck Sues Fresenius To Block Integrilin Generic

Law360, New York (November 13, 2012, 3:53 PM EST) -- Subsidiaries of Merck & Co. Inc. and Takeda Pharmaceutical Co. Ltd on Friday sued Fresenius SE & Co. KGaA's U.S. entities for patent infringement in Delaware court, seeking to block their plans to market a generic version of blood thinner Integrilin.

Merck Sharp & Dohme Corp. and Takeda's Millennium Pharmaceutical Inc. claim Fresenius, based in Homburg, Germany, and its APP Pharmaceuticals Inc. unit are planning to bring a copycat version of Integrilin before patents covering the anticlotting drug and its use expire.

Integrilin is intended to treat...
To view the full article, register now.